Ignite Creation Date:
2024-05-06 @ 12:00 AM
Last Modification Date:
2024-10-26 @ 10:42 AM
Study NCT ID:
NCT01462448
Status:
UNKNOWN
Last Update Posted:
2019-04-10
First Post:
2011-10-24
Brief Title:
Study to Identify the Genetic Variations Associated With Phantom Limb Pain
Sponsor:
Henry M Jackson Foundation for the Advancement of Military Medicine
Organization:
Henry M Jackson Foundation for the Advancement of Military Medicine
Study Overview
Official Title:
Study to Identify the Genetic Variations Associated With Phantom Limb Pain
Status:
UNKNOWN
Status Verified Date:
2019-04
Last Known Status:
ACTIVE_NOT_RECRUITING
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The purpose of this study is to determine if there is a genetic component to phantom limb pain DNA will be analyzed for single nucleotide polymorphisms SNPs between the control and phantom limb pain group Total RNA will also be isolated and profiled to asses the degree to which our genes of interest are expressed in the presence or absence of phantom limb pain Some proteins such as inflammatory antibodies or the neurotrophin brain-derived neurotrophic factor BDNF will also be assessed for their associations with phantom limb pain
Detailed Description:
Most patients 90-95with major limb amputations experience a phantom limb--the vivid impression that the limb is still present In many cases the sensation is painful for reasons that are currently not well understood A small subset of amputees 10 never experience phantom limb pain PLP the painful sensation felt in the amputated limb This difference suggests that there may be a genetic component that precludes some patients from ever experiencing PLP Understanding the genetic components of PLP may help in predicting which patients will experience PLP and which amputees will respond to the various treatment options available
In order to understand the genetic aspects and ultimately develop more effective treatment options in the future patients with and without PLP will be asked to give 30 mls of blood after overnight fasting These blood samples will be de-identified and sent to the National Institutes of Health NIH in Bethesda Maryland where all of the genetic analyses will take place
In order to understand the genetic aspects and ultimately develop more effective treatment options in the future patients with and without PLP will be asked to give 30 mls of blood after overnight fasting These blood samples will be de-identified and sent to the National Institutes of Health NIH in Bethesda Maryland where all of the genetic analyses will take place
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| HU0001-11-1-0005 | OTHER_GRANT | Uniformed Services University of Health Sciences USUHS | None |